Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
Launched by PHARMACIA · Aug 30, 2001
Trial Information
Current as of March 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Concurrent Medication:
- Allowed:
- • Any medication with the exception of other investigational drugs not available under a treatment IND, expanded access, or parallel track program.
- Patients must have:
- • Confirmed HIV infection.
- • CD4 cell counts \<= 200 cells/mm3.
- • No evidence of disseminated MAC disease.
- • Informed consent of parent or guardian if 12 to \< 18 years of age.
- NOTE:
- • Pregnant females may be eligible. There are no studies of the safety or efficacy of rifabutin in pregnant women. Rifabutin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In addition, a risk/benefit decision should consider the likelihood of a woman's developing MAC if she does not receive prophylaxis. The risk of developing MAC rises substantially for women with CD4 counts less than 100, although it can also develop in women with higher CD4 counts. Women of reproductive potential who are not pregnant must use contraception. They are encouraged to use means other than oral contraceptives.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms and conditions are excluded:
- • Known hypersensitivity to rifabutin, rifampin, or other rifamycins.
- • Current infection due to MAC or other mycobacterial disease, or complaints consistent with tuberculosis.
- Concurrent Medication:
- Excluded:
- • Other investigational drugs with the exception of those available under a treatment IND, expanded access, or parallel track program. (Licensed products prescribed for unlabeled indications are not considered investigational.)
- Patients with the following prior conditions are excluded:
- • Prior infection due to MAC or other mycobacterial disease or complaints consistent with tuberculosis.
About Pharmacia
Pharmacia is a global biopharmaceutical company dedicated to advancing healthcare through innovative research and development. With a strong focus on delivering effective therapies for a range of medical conditions, Pharmacia harnesses cutting-edge science and technology to create solutions that enhance patient outcomes. The company is committed to conducting rigorous clinical trials that adhere to the highest ethical and scientific standards, ensuring the safety and well-being of participants while contributing to the advancement of medical knowledge. Through collaboration with healthcare professionals and regulatory bodies, Pharmacia strives to bring transformative treatments to market that address unmet medical needs and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Davids, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials